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ABSTRACT Protein tyrosine phosphatases (PTPs) have
long been thought to play a role in tumor suppression due to
their ability to antagonize the growth promoting protein
tyrosine kinases. Recently, a candidate tumor suppressor
from 10q23, termed P-TEN, was isolated, and sequence ho-
mology was demonstrated with members of the PTP family, as
well as the cytoskeletal protein tensin. Here we show that
recombinant P-TEN dephosphorylated protein and peptide
substrates phosphorylated on serine, threonine, and tyrosine
residues, indicating that P-TEN is a dual-specificity phospha-
tase. In addition, P-TEN exhibited a high degree of substrate
specificity, showing selectivity for extremely acidic substrates
in vitro. Furthermore, we demonstrate that mutations in
P-TEN, identified from primary tumors, tumor cells lines, and
a patient with Bannayan–Zonana syndrome, resulted in the
ablation of phosphatase activity, demonstrating that enzy-
matic activity of P-TEN is necessary for its ability to function
as a tumor suppressor.
A variety of techniques have been used to identify genes
involved in the etiology of cancer. From these studies, a
surprisingly large number of protein tyrosine kinases (PTKs)
have been implicated in carcinogenesis (1). The PTKs are
activated by amplification, deletion, or mutation of important
negative regulatory domains, or by genetic rearrangements
that result in the production of activated fusion proteins (1, 2).
Further support for the importance of tyrosine phosphoryla-
tion in oncogenesis comes from the finding that expression of
v-crk, a small adaptor protein that does not contain intrinsic
PTK activity, results in an increase in the levels of cellular
phosphotyrosine and cellular transformation (3). The critical
role that tyrosine phosphorylation plays in oncogenesis has led
to the suggestion that many protein tyrosine phosphatases
(PTPs) would act as tumor suppressors. Although PTPs have
been linked to the inhibition of cell proliferation, there had
been no clear cut examples of these enzymes functioning as
tumor suppressors.
P-TEN, a candidate tumor-suppressor gene identified on
chromosome 10, also known as MMAC1, shares homology
with the PTP family, as well as with the cytoskeletal protein
tensin (4, 5). P-TEN was isolated from a locus on chromosome
10, 10q22-23, which is deleted in a large number of tumors,
especially glioblastomas (4, 5). Subsequently, it was shown that
P-TEN is deleted or mutated in a significant fraction of
glioblastomas and prostate tumors (4, 5). Importantly, germ-
line mutations in P-TEN give rise to Cowden disease, which is
typified by the formation of multiple, benign tumors and an
increased susceptibility to malignant cancers. Mutations in
P-TEN were also found in patients suffering from disorders
similar to Cowden disease, such as Lhermitte–Duclos disease,
which has additional pathologies, including ataxia, macroceph-
aly, and dysplastic cerebellar gangliocytomatosis (6, 7). The
detection of germ-line mutations in four of five Cowdeny
Lhermitte–Duclos kindreds verified that P-TEN functions as
a tumor suppressor and also suggests that P-TEN plays a role
in the proper development and formation of certain tissues (8).
Recent data also suggest that germ-line mutations of P-TEN
are also responsible for Bannayan–Zonana syndrome (C.E.,
unpublished data), an autosomal dominant disorder, that in
addition to the mental retardation, macrocephaly, and thyroid
disease shared with Cowden disease, is characterized by lipo-
matosis, speckled penis, and an early onset of the neoplastic
disease (9).
All PTPs contain the catalytic signature motif
HCXXGXXRSyT (10). The cysteine residue in this motif is
absolutely required for catalysis, as it acts as a nucleophile to
attack the phosphorous atom in the phosphate moeity of its
substrate, forming a thiol-phosphate intermediate (11). Mu-
tation of this cysteine to serine or alanine results in the
complete loss of phosphatase activity (12). The dual-specificity
phosphatases, which catalyze the hydrolysis of phospho-seryl,
-threonyl, and -tyrosyl residues, also contain the canonical
PTP catalytic motif (13). The crystal structure of PTP1B, the
prototypic PTP, reveals that the stringent amino acid selec-
tivity of the PTPs is determined, in part, by the location of the
catalytic cysteine at the base of a cleft (11, 14). The depth of
the cleft (9 Å) matches the length of a phosphotyrosine residue
and the shorter phospho-seryl and -threonyl residues are not
able to reach the catalytic cysteine. In addition, the deep cleft
is lined with hydrophobic residues that help stabilize the
interaction with the hydrophobic tyrosine moiety (12). In
contrast to PTP1B, the phosphate-binding loop in the dual-
specificity phosphatase VHR is at the base of a much shallower
cleft, which can accommodate all three phosphorylated hy-
droxyl amino acids (15). Regardless of the depth of the
catalytic pocket, both classes of enzymes proceed through
similar steps of catalysis. The initial nucleophilic attack of the
cysteine residue results in the formation of an enzyme–
substrate complex. This complex is disrupted by the catalytic
acid (Asp-181 in PTP1B and Asp-92 in VHR) which proto-
nates the phenolic oxygen of the tyrosyl group, releasing the
dephosphorylated substrate from the complex. The phospho-
rous atom remains associated with the active site cysteine as a
thiol–phosphate. In the case of the PTPs, the active enzyme is
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regenerated by the hydrolysis of the thiol–phosphate bond by
a water molecule, possibly activated by the same aspartate
residue (11, 14, 15). The efficiency of this reaction is illustrated
by the finding that PTP1B can undergo '2,000 catalytic cycles
per minute (12).
Recent data indicate that the PTPs exhibit a great deal of
substrate specificity in vivo and are not simply unregulated
antagonists of the signals mediated by the PTKs (12, 16). In
fact, PTPs can exert both positive and negative effects on
signaling pathways, indicating that they do not simply function
as ‘‘off switches’’ (17, 18). In spite of the large number of PTKs
that have been shown to play a role in oncogenesis (1), there
were no examples of PTPs that function as classical tumor
suppressors. Although P-TEN has been identified as a tumor
suppressor and displays some of the structural features of the
PTP family, its phosphatase activity has not been character-
ized. We have expressed P-TEN in Escherichia coli as a
glutathione S-transferase (GST) fusion protein and demon-
strated that P-TEN is catalytically active. Purified GST–P-
TEN showed a strong preference for only the most acidic
substrates. Furthermore, P-TEN was able to dephosphorylate
serine, threonine, and tyrosine residues, establishing it as a
dual-specificity phosphatase. Finally, we demonstrated that
the phosphatase activity of P-TEN is necessary for its ability
to function as a tumor suppressor, because a variety of point
mutations, derived from tumor samples or Bannayan–Zonana
syndrome, ablated P-TEN activity.
MATERIALS AND METHODS
Expression and Purification of GST–P-TEN. A full-length
P-TEN cDNA was generated by ligating the NotI–BglII frag-
ment from EST264611 with the BglII–EcoRI fragment of
EST365465 into pBluescript digested with NotI–EcoRI. The
resulting full-length P-TEN cDNA was amplified by PCR using
pfu polymerase (Stratagene) and primers that add a 59 BamHI
site (59-CGCGGATCCATGACAGCCATCATCAAA-
GAGATCGTTAGC) and a 39 EcoRI site (59-CGCGAAT-
TCTCAGACTTTTGTAATTTGTGTATGC). The resulting
fragment was subcloned into pGEX2T (Pharmacia), and the
sequence was verified by automated sequencing. Expression of
P-TEN was induced in 500 ml of mid-log phase bacteria (A600
5 0.600) by the addition of isopropyl b-D-thiogalactoside to
200 mM. The culture was shifted to room temperature and
expression was allowed to proceed for 12 h. The bacteria were
harvested by centrifugation, the supernatant was removed, and
the bacterial pellet was frozen at 280°C. The frozen pellets
were resuspended in 5 ml of ice cold 20 mM Tris, 150 mM
NaCl, and 5 mM EDTA (pH 8.0) supplemented with lysozyme
(1 mgyml), aprotinin (5 mgyml), leupeptin (5 mgyml), and
benzamidine (1 mM) and incubated on ice for 15 min. The
bacteria were lysed by sonicating three times for 1 min each
with a Branson model 450 sonifier, power setting 4, 70% duty
cycle. The lysate was cleared by centrifugation at 30,000 3 g for
10 min, diluted with an equal volume of HBS (50 mM
Hepesy150 mM NaCl, pH 7.4). Glutathione-Sepharose 4B
(300 ml) was added, and the resulting slurry was incubated at
4°C on a rocking platform for 1–2 h. The glutathione-
Sepharose was washed five times, each with 10 ml of ice cold
HBS, and the washed fusion proteins were eluted with a
solution containing 20 mM glutathione, 50 mM Hepes, and
30% glycerol (pH 8.0). Protein concentrations were deter-
mined by the method of Bradford, using BSA as a standard,
and the integrity of the fusion proteins were verified by
SDSyPAGE. Mutations identified from tumor samples and
cell lines [refs. 4 and 5; and L. Hedrick (Johns Hopkins
University) personal communication] or identified from Cow-
den disease (8) and Bannayan–Zonana (C.E., unpublished
data) were introduced into pGEX2T–P-TEN using the Quick-
change mutagenesis kit as described by the manufacturer
(Stratagene). For all mutations, the entire P-TEN ORF was
sequenced to confirm that no other mutations had been
introduced.
Substrate Preparation. All tyrosine-phosphorylated sub-
strates were phosphorylated with the cytoplasmic fragment of
the b subunit of the insulin receptor kinase (b-IRK) and
purified as described (19). Serine-phosphorylated substrates
were phosphorylated with recombinant protein kinase A (New
England Biolabs) or with recombinant casein kinase II (a gift
from D. Litchfield, University of Western Ontario) in a
reaction mixture consisting of 50 mM Hepes (pH 7.2), 10 mM
MgCl2, 2 mM DTT, 2 mM ATP, and 1 mCi of [g-32P]ATP (1
Ci 5 37 GBq) in a total volume of 1 ml. Casein was used at a
concentration of 10 mgyml, myelin basic protein (MBP) at 4
mgyml, and the peptides RRRDDDSDDD (DSD) and
RRREEETEEE (ETE) were used at a concentration of 0.5
mgyml. Protein substrates were precipitated by the addition of
ammonium sulfate to 80%, incubated on ice for 30 min, and
harvested by centrifugation. The precipitated proteins were
washed three times with 80% ammonium sulfate and then
resuspended in 500 ml of 1 M Hepes (pH 7.5). The solubilized
proteins were dialyzed against several changes of 50 mM
imidizole (pH 7.2). Peptide substrates were purified using a
Sep-pak C18 reverse phase cartridge (Waters) as described
(20). The purified peptides were lyophilized to dryness and
resuspended in 50 mM imidizole (pH 7.2). Random copoly-
mers of glutamate and tyrosine, with a 4:1 ratio of glutamate
to tyrosine (polyGlu4Tyr1) or with a 1:1 ratio (polyGlu1Tyr1),
were purchased from Sigma and phosphorylated with b-IRK
at a final polymer concentration of 1 mgyml and purified, as
described, using Sep-pak C18 reverse phase chromatography.
Phosphorylated ERK2 was produced in E. coli by coexpression
of activated MEK and was a gift from D. Barford (Oxford
University).
Phosphatase Assays. The standard phosphatase assay con-
tained 10 mM substrate, 50 mM Hepes (pH 7.0), 10 mM MgCl2,
and 10 mM DTT. The reaction was initiated by the addition of
enzyme, typically 1–2 mg, to prewarmed (30°C) substrate mix,
resulting in a final volume of 60 ml. The reactions were allowed
to proceed at 30°C for the indicated times and stopped by the
addition of a suspension of activated charcoal in 900 mM HCl,
90 mM NaPPi, and 2 mM NaPi (21). Dephosphorylation of
ERK2 was performed essentially as described for the radio-
active substrates; at the indicated times duplicate aliquots were
removed and stopped by the addition of 53 Laemmli sample
buffer and processed for immunoblot analysis as described
(20). Immunoblots were probed with a 1:5,000 dilution of
anti-mitogen-activated protein (MAP) kinase ascites or with a
mixture of anti-phosphotyrosine antibodies [1:2,000 dilution of
G-104 and G-2-98 ascites (22)] and were developed with ECL
reagents (Amersham) in conjunction with an horseradish
peroxidase-labeled rat anti-mouse k-chain antibody (Zymed).
RESULTS
Although P-TEN displays structural features of members of
the PTP family of enzymes an important, and essential, step
toward understanding the function of P-TEN is the charac-
terization of its enzymatic activity. To test whether P-TEN
encodes an active phosphatase, we expressed it as a fusion
protein in E. coli. As a control, we assayed all substrates with
a mutant of P-TEN in which the essential cysteine from the
signature motif had been mutated to serine (P-TENC124S).
This mutant would be expected to be catalytically inactive, and
ensures that any activity seen was the result of P-TEN and not
of a copurifying bacterial phosphatase.
PTP Activity of P-TEN. Initially, we assayed P-TEN against
a number of tyrosine-phosphorylated proteins and peptides,
including reduced carboxyamidomethylated and maleylated
lysozyme (RCML), MBP, polyGlu4Tyr1, and polyGlu1Tyr1, as
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well as the peptide EDNDYINASL. The activity of P-TEN
toward the classical substrates RCML and MBP was weak
(,80 pmolymin per mg). However, P-TEN, exhibited robust
phosphatase activity when polyGlu4Tyr1 was used as a sub-
strate (4,840 pmolymin per mg) (Table 1 and Fig. 1A).
Significantly, addition of unphosphorylated polyGlu4Tyr1 to
reactions using RCML as a substrate did not result in an
increase in activity toward RCML (data not shown), indicating
that P-TEN was not activated by the polyanionic character of
polyGlu4Tyr1. In fact, inclusion of unphosphorylated
polyGlu4Tyr1 in reactions containing RCML resulted in the
inhibition of the already limited dephosphorylation of RCML,
suggesting that even unphosphorylated polyGlu4Tyr1 was ca-
pable of binding to P-TEN, displacing the more weakly inter-
acting RCML. We also observed that P-TEN dephosporylated
polyGlu1Tyr1. When the stoichiometries of phosphorylation
were normalized, no significant differences were detected in
the rates of dephosphorylation of polyGlu4Tyr1 and
polyGlu1Tyr1, suggesting that the acidic character of these
substrates is an important determinant of substrate recogni-
tion. P-TEN, however, exhibited reduced activity when assayed
with the acidic peptide EDNDYINASL (Table 1), suggesting
that the mere presence of acidic residues was not sufficient to
ensure that a peptide would be a substrate. cdc14, a dual-
specificity phosphatase that is closely related to P-TEN (8),
does not discriminate between RCML and polyGlu4Tyr1 (Fig.
1B), indicating that polyGlu4Tyr1 is not a universal substrate
for the dual-specificity phosphatases, and that the substrate
specificity of P-TEN is likely to be unique feature determined
by structural motifs separate from the catalytic motif. Caution
should be exercised when comparing the activity of P-TEN to
that of other dual-specificity phosphatases because of the
inherent substrate specificity exhibited by these enzymes.
Dual-Specificity Phosphatase Activity of P-TEN. To test
whether P-TEN falls into the class of dual-specificity phos-
phatases, we assayed activity using a number of proteins and
peptides phosphorylated on serine and threonine residues.
Similar to the findings with tyrosine-phosphorylated sub-
strates, P-TEN dephosphorylated serineythreonine residues in
substrates that had a preponderance of acidic residues. Spe-
cifically, P-TEN dephosphorylated two peptide substrates
(DSD and ETE) with the highest efficiency (Table 1 and Fig.
2). Furthermore, P-TEN showed specificity even among acidic
serineythreonine substrates, exhibiting a reduced activity when
casein, phosphorylated by casein kinase II or protein kinase A,
was used as substrate (Table 1 and Fig. 2). As might be
anticipated in light of these properties, P-TEN exhibited
almost undetectable activity when assayed with polybasic
substrates, such as MBP or Kemptide (LRRASLG) (Fig. 2 and
data not shown). The finding that P-TEN dephosphorylated
two peptide substrates of casein kinase II also indicates that the
inability of P-TEN to dephosphorylate EDNDYINASL does
not simply reflect its inability to dephosphorylate small pep-
tide substrates. Although many dual-specificity phosphatases
show a preference for tyrosine residues, it is possible that the
reduction in the activity of P-TEN toward serineythreonine
substrates may be the result of these residues being located in
a suboptimal substrate backbone.
Dephosphorylation of ERK2. A number of dual-specificity
phosphatases show a preference for members of the MAP
kinase family (13, 23, 24). Therefore, we tested whether P-TEN
could dephosphorylate ERK2. We could not detect dephos-
phorylation of ERK2 by P-TEN, either by changes in anti-
phosphotyrosine antibody reactivity or by changes in the
electrophoretic mobility of ERK2. In contrast, MAP kinase






polyGlu4Tyr1 4,840 6 140
RCML 88 6 6.6
EDNDYINASL peptide 51 6 4.0
MBP 21 6 1.2
Phospho-seryl and -threonyl substrates
DSD peptide 210 6 4.2
ETE peptide 161 6 1.8
Casein (casein kinase II) 14.2 6 1.2
Casein (protein kinase A) 27.5 6 2.2
MBP 11.3 6 0.6
P-TEN activity was measured with the indicated substrates in
triplicate. The activity is expressed as the mean pmol phosphate
released per min per mg enzyme 6 SD.
FIG. 1. Tyrosine phosphatase activity of purified P-TEN. (A)
P-TEN was tested for protein phosphatase activity using the indicated
tyrosine-phosphorylated substrates. Activity is expressed as pmol of
phosphate released. A catalytically inactive mutant of P-TEN (P-
TENC124S) was included as a control to rule out the possibility of
contaminating bacterial phosphatases. (B) Comparison of P-TEN and
cdc14 activities. P-TEN and cdc14 were assayed as above with RCML
or polyGlu4Tyr1, and the activity is expressed as pmol of phosphate
released per min per mg.
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phosphatase 1 (MKP-1) quickly and completely dephospho-
rylated ERK2, as shown by the removal of phosphotyrosine
from ERK2 and an increase in its electrophoretic mobility
(Fig. 3 A and B, respectively).
Effects of Point Mutations on the Activity of P-TEN. To test
whether the activity of P-TEN was altered during tumorigen-
esis, we assessed the effect on activity of a variety of point
mutations that occur in P-TEN isolated from tumor specimens.
Many of these mutations occur in or near the catalytic motif
of P-TEN, including His-1233 Tyr (H123Y), Gly-1293 Arg
(G129R) or Gly-129 3 Glu (G129E), and Met-134 3 Leu
(M134L). In addition, several mutations were found that
occurred outside the conserved catalytic motif, including
Leu-57 3 Trp (L57W) and a cluster of mutations C terminal
to the catalytic loop [Gly-1653 Arg (G165R), Thr-1673 Pro
(T167P), and Ser-1703 Arg (S170R)]. The exact positions of
these mutations in P-TEN are indicated in Fig. 4. We produced
GST fusion proteins in which P-TEN was mutated at each of
these positions to mimic the mutant alleles, and the phospha-
tase activity of the resulting recombinant proteins was mea-
sured using polyGlu4Tyr1 as a substrate (Fig. 5). With the
exceptions of the M134L and the G129E mutation, all the
mutations tested resulted in a dramatic decrease in the activity
of P-TEN (Fig. 5). These data indicate that the catalytic
activity of P-TEN has been disrupted in the majority of these
tumors.
The activity exhibited by the G129E mutation was surpris-
ing, especially in light of the finding that mutation of this same
residue to arginine (G129R) resulted in a significant reduction
of P-TEN activity. Other potential effects of this mutation on
P-TEN, such as changes in protein stability in the complex
environment of the mammalian cell or changes in substrate
specificity, have not been addressed. On the other hand, the
essentially wild-type activity exhibited by the M134L mutation
was not totally unexpected because many other dual-specificity
phosphatases contain a leucine residue at this position (25).
DISCUSSION
The most common chromosomal deletion in glioblastoma
occurs around 10q22-23, suggesting the presence of a tumor
suppressor at this locus (26). Mapping of the deletions at
10q22-23, as well as representational difference analysis (27),
led to the identification of P-TEN as the tumor suppressor
residing at this locus (4, 5). P-TEN shares sequence homology
with the cytoskeletal protein tensin and with the family of
PTPs (4, 5). A substantial fraction of all glioblastoma samples
tested have either deleted or mutated P-TEN alleles. In
addition, P-TEN has been shown to be disrupted in a large
number of breast and prostate tumor samples (4, 5). Impor-
tantly, germ-line mutations in P-TEN give rise to a variety of
genetic disorders, most notably Cowden disease, a disorder
characterized by the formation of multiple benign tumors
(hamartomas), as well as an increased susceptibility to malig-
nant cancers of the breast and thyroid (28), confirming that
P-TEN functions similarly to classical tumor-suppressor genes
(8). Significantly, many of the mutations isolated from tumor
samples, as well as from Cowden disease and Bannayan–
Zonana syndrome, were predicted to disrupt the phosphatase
domain of P-TEN. These studies, however, did not address
whether P-TEN is a functional phosphatase or whether these
mutations abrogate activity.
To address these issues, we measured the enzymatic activity
of recombinant P-TEN. Initially, we were frustrated by the low
activity of the fusion proteins when assayed with proteins that
are commonly used as PTP substrates, such as RCML or MBP.
Recently, another group has also reported weak phosphatase
activity when RCML was used as a substrate (29). However, we
demonstrate that P-TEN exhibits robust phosphatase activity
when assayed with a random copolymer of glutamate and
tyrosine, polyGlu4Tyr1, suggesting that it exhibits an unusual
substrate specificity. P-TEN did not efficiently dephosphory-
late the acidic peptide EDNDYINASL, suggesting that the
presence of acidic residues may not be sufficient to create an
optimal substrate and that higher order structures, such as
those found in protein substrates, may be required.
On the basis of the presence of the ‘‘AYLLyM’’ motif found
in many dual-specificity phosphatases, as well as the absence
of some of the sequence motifs found in PTPs, particularly
those that contribute to creating a deep, substrate-binding cleft
(30), one would predict that P-TEN is a dual-specificity
FIG. 2. Dual-specificity phosphatase activity of purified P-TEN.
P-TEN was tested for protein phosphatase activity using the indicated
serineythreonine-phosphorylated substrates. Activity is expressed as
pmol of phosphate released. A catalytically inactive mutant of P-TEN
(P-TENC124S) was included to control for contaminating bacterial
phosphatases. Casein was phosphorylated, as indicated, with casein
kinase II (CKII) or protein kinase A (PKA).
FIG. 3. P-TEN does not dephosphorylate ERK2. Phosphorylated
ERK2 was incubated with P-TEN or MKP-1 for the indicated times
and ERK2 assayed for residual phosphotyrosine by immunoblotting
(A) with an anti-phosphotyrosine antibody or (B) by immunoblotting
with anti-MAP kinase antibodies to visualize the change in electro-
phoretic mobility.
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phosphatase. P-TEN was shown to exhibit activity against
serineythreonine, as well as tyrosine-phosphorylated proteins
(Table 1), verifying that it is a dual-specificity phosphatase.
Like the tyrosine-phosphorylated substrates, P-TEN dephos-
phorylated only the most acidic serineythreonine-phosphory-
lated substrates tested. Even the best serineythreonine sub-
strates, the ETE and DSD peptides, were not as efficiently
dephosphorylated as polyGlu4Tyr1 (Table 1). Casein, phos-
phorylated by casein kinase II, was dephosphorylated poorly
by P-TEN (Table 1 and Fig. 2), suggesting that P-TEN may
require multiple acidic residues positioned both N and C
terminally to the phosphorylated residue. It is currently un-
clear if the apparent amino acid selectivity of P-TEN is an
intrinsic characteristic or if it is caused by differences in the
affinity of P-TEN for polyGlu4Tyr1 and the ETE or DSD
peptides, and may reflect a preference for protein over peptide
substrates.
Mutations that occur in P-TEN during tumorigenesis fall
into three large classes: (i) genomic deletions encompassing all
or most of P-TEN, (ii) frameshift mutations resulting in the
production of truncated P-TEN proteins, and (iii) point mu-
tations resulting in the substitution of one amino acid for
another (4, 5). We have chosen to introduce a variety of the
point mutations found in tumor samples into P-TEN, because
they are less likely than the frameshift deletions to cause
unpredictable changes in the conserved secondary structure
found in all PTPs (30). Comparisons of P-TEN with other
phosphatases, whose crystal structures have been solved, aids
in predicting how these point mutations might disrupt P-TEN
activity. For example, the mutation of His-1233 Tyr (H123Y)
and Gly-1293Arg, two residues located in the catalytic motif,
resulted in the complete loss of phosphatase activity. One
would have predicted that the H123Y mutation, detected in an
endometrial cancer, would be catastrophic to activity because
of the critical importance of this histidine in correctly orienting
the catalytic cysteine so it can act as a nucleophile (11).
Although, Gly-129 is not as highly conserved as other residues
found in the catalytic motif, the substitution of the large,
positively charged side chain of arginine, a mutation found in
a glioblastoma cell line, for the much smaller glycine, is likely
to have a deleterious effect on the overall structure of the
phosphate-binding loop and is likely to impede the binding of
phosphate. In contrast, a mutation that was identified in a
prostate tumor cell line, in which Met-134 was changed to Leu
(M134L), had no effect on P-TEN activity. However, among
the dual-specificity phosphatases, leucine is commonly found
at this position (25), suggesting that the M134L allele may
represent a naturally occurring polymorphism rather than a
mutation.
Several other mutations that reside outside of the catalytic
motif were also tested for their effect on P-TEN activity. A
point mutation discovered in a glioblastoma sample that
changes Leu-57 3 Trp (L57W) also eliminated P-TEN phos-
phatase activity. This amino acid is located in a conserved
a-helix (a2), which is found in both PTP1B and VHR.
Although not directly involved in catalysis, this helix helps
form the overall secondary structure of the enzyme (14, 15).
Similarly, mutation of residues in this helix of LAR, a receptor
PTP, also resulted in a significant loss of phosphatase activity
(31). A second cluster of point mutations was discovered in the
last conserved structural motif found in most PTPs and
dual-specificity phosphatases, which also is an a-helix (14, 15).
In YopH, a PTP isolated from the causative agent of bubonic
plague, a hydrophobic residue in this a-helix is important for
coordinating the water molecule necessary for regenerating
the active enzyme (15). All three mutations found in this
region—Gly-1653 Arg (found in a glioblastoma), Thr-1673
Pro (found in a breast cancer), and Ser-703 Arg (found in a
patient with a Bannayan–Zonana syndrome)—resulted in the
loss of P-TEN activity. The G165R and the S170R mutations
would result in substitution of relatively small, uncharged
amino acids for a much larger positively charged residue,
potentially disrupting important interactions between this
a-helix and surrounding structures. Moreover, the substitution
of Thr-1673 Pro is also likely to disrupt these interactions by
interrupting the proper folding of this a-helix. These data
indicate that this conserved helix (a7 in YopH and VHR) is a
required motif in the dual-specificity phosphatases.
All of the mutations tested were derived from tumor samples
that, with two exceptions, resulted in the complete loss of, or
greatly reduced, enzymatic activity of P-TEN, even when the
mutations resided well outside of the conserved catalytic
motif. These observations indicate that the inhibition of en-
FIG. 5. Disruption of P-TEN activity by point mutations found in
tumor samples. The indicated point mutations were introduced into
recombinant P-TEN and their effects on phosphatase activity were
determined. Assays were performed with polyGlu4Tyr1 for 15 min.
Activity is expressed as pmol of phosphate liberated per min per mg
of P-TEN. Assays were performed in triplicate and are expressed as
the mean 6 SD. The catalytically inactive mutant of P-TEN (P-
TENC124S) was included as control to rule out the possibility of
contaminating bacterial phosphatases.
FIG. 4. Location of P-TEN mutations. A diagram of P-TEN showing the locations of the point mutations, indicated by an p, that were tested
in this study. In addition, the predicted structural motifs (see text) in which these mutations lie is also indicated.
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zymatic activity was required for the progression of these cells
to a cancerous state.
M134L was one of two mutations found in which activity was
not lost. However, leucine is commonly found at this position
in other dual-specificity phosphatases (25) and the wild-type
allele was not lost in the tumor from which this mutation
derived. Hence, M134L is likely to be a naturally occurring
polymorphism.
We were surprised by the finding that the G129E mutation,
a mutation found in the germ line of patients suffering from
Cowden disease, did not disrupt P-TEN activity, whereas a
mutation of this same residue to arginine (found in a glioblas-
toma) ablated P-TEN activity. Although we were unable to
detect a change in the activity of P-TEN carrying the G129E
mutation, it is likely that this mutation effects the ability of
P-TEN to function in vivo, as this mutation has been isolated
from two independent Cowden disease kindreds but not from
unaffected patients (8). Moreover, deletions of the wild-type
allele were found in the tumors that develop in this Cowden
disease kindred (8). Although the G129E mutation does not
effect activity when measured in vitro using artificial substrates,
this mutation may interfere with the ability of P-TEN to
dephosphorylate its physiological targets. Furthermore, this
mutation may decrease the stability or half-life of P-TEN in the
complex environment of the mammalian cell. A full under-
standing of the effects of this mutation on P-TEN will require
the identification of its physiological substrates, regulators and
perhaps even the elucidation of the structural changes elicited
by this amino acid substitution.
Even though the sample size is small, there does appear to
be a correlation between the severity in the disruption of
P-TEN activity and the pathology of the disease. In contrast to
the G129E mutation, the S170R mutation exhibited a signif-
icant reduction in activity and was isolated from a patient
suffering from a severe disorder, Bannayan–Zonana, that
shares many features with Cowden disease, but also manifests
additional pathologies, including early onset of the disease at
birth (9).
To understand how P-TEN functions as tumor suppressor,
it will be necessary to identify its physiological substrates. Most
dual-specificity phosphatases dephosphorylate and inactivate
the MAP kinases (13, 23, 24), and moreover, the MAP kinases
are found to be hyperphosphorylated in breast cancer (32), a
cancer that frequently contains P-TEN mutations or deletions
(8). Therefore, we tested if P-TEN could dephosphorylate the
MAP kinase ERK2. However, our data indicate that P-TEN
was incapable of dephosphorylating ERK2 in vitro, strongly
suggesting that the MAP kinases are not regulated by P-TEN
in vivo. Thus, the physiological substrates of P-TEN are still
unknown. The unique substrate specificity of P-TEN, however,
should aid in identifying its in vivo substrates. Importantly, the
requirement for acidic residues may be satisfied by the pres-
ence of phosphorylated residues, suggesting that multiply
phosphorylated proteins may serve as P-TEN substrates.
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